Nature Research Round Table: Genome Editing in Human Pluripotent Stem Cells
Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute discusses considerations for genome editing in human pluripotent stem cells (hPSCs). Dr. Vallier is involved at the Cambridge Biomedical Research Center Core Facility, whose services include providing genome-edited iPS cell lines for disease modeling and developing approaches for cell-based therapies. This presentation and the following Q&A session were moderated by Dr. Alex Alderton from the Wellcome Trust Sanger Institute.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Publish Date: November 01, 2019
Views: 0
Related Multimedia
-
Nature Research Round Table: Best Practices for the QC of Genome-Edited hPSC Lines - Panel Discussion
Publish Date: November 01, 2019 -
Optimized Workflows for High-Efficiency Genome Editing in Stem and Primary Cell Types
Publish Date: September 09, 2019 -
Nature Research Round Table: Identifying Acquired and Background Genetic Variants in Human Pluripotent Stem Cells
Publish Date: November 01, 2019
Explore Our Products
-
Feeder-free, animal component-free culture medium for maintenance of human ES and iPS cells -
Enhanced green fluorescent protein (eGFP)-tagged Cas9 nuclease for the generation of double-strand breaks in CRISPR-Cas9 genome editing -
cGMP, stabilized feeder-free maintenance medium for human ES and iPS cells -
qPCR analysis kit for detecting the majority of karyotypic abnormalities reported in human ES and iPS cells
